 PDS Biotechnology Corporation NASDAQ:PDSB, a clinical-stage immunotherapy company owned by NetScientific, has reported expanded interim data from a Phase-2 clinical trial of its PDS0101 triple combination therapy for advanced, refractory human papillomavirus HPV-positive cancers. All patients in the study had failed prior treatment with chemotherapy and 90 had failed radiation treatment. 